arm 1

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Small Cell Lung CancerUterine Fibroid

598 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Taxol

Teva

Phase 3

342

Gemzar

Johnson & Johnson

Phase 3

263

Camptosar

Pfizer

Phase 3

264

Keytruda

Merck & Co.

Phase 3

205

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

986

Vepesid

AAvyxa

Phase 3

1157

Opdivo

Bristol-Myers Squibb

Phase 3

168

Yervoy

Bristol-Myers Squibb

Phase 3

119

Tarlatamab-Dznl

Amgen

Phase 3

1010

Lynparza

AstraZeneca

Phase 3

10Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Infusion1 trial

A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion

Completed·Eisai·Phase 1·NCT01308541·20 enrolled

Uterine Fibroid1 trial

Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation

Not yet recruiting·KKaohsiung Medical University·Phase 4·NCT06640738·60 enrolled

Metastatic Head and Neck Cancer1 trial

Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Completed·Amgen·Phase 3·NCT00460265·658 enrolled

Small Cell Lung Cancer1 trial

A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06620796·70 enrolled

Efficacy and Safety1 trial

Study of of URC102 to Assess the Efficacy and Safety in Gout Patients

Completed·JJW Pharmaceutical·Phase 2·NCT04804111·171 enrolled

Details

Drug Info

Related News